Profile
Sector:
HealthcareIndustry:
Medical DevicesCountry:
United StatesIPO:
12 June 2018Website:
http://www.beyondair.netNext earnings report:
09 August 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | 13 min agoDividend
Analysts recommendations
Institutional Ownership
XAIR Latest News
Beyond Air, Inc. (XAIR) came out with a quarterly loss of $0.36 per share versus the Zacks Consensus Estimate of a loss of $0.47. This compares to loss of $0.67 per share a year ago.
Beyond Air, Inc. (NASDAQ:XAIR ) Q4 2024 Earnings Call Transcript June 24, 2024 4:30 PM ET Company Participants Garth Russell - Investor Relations, LifeSci Advisors Steve Lisi - Chairman and Chief Executive Officer Douglas Larson - Chief Financial Officer Conference Call Participants Marie Thibault - BTIG Yale Jen - Laidlaw & Company Matt Kaplan - Ladenburg Thalmann Operator Good afternoon, and welcome, everyone to the Beyond Air Financial Results Call for the Fiscal Quarter Ended March 31, 2024. At this time, participants are in a listen-only mode.
Mr. Webster brings more than 20 years of executive level experience in the life sciences industry Mr. Webster brings more than 20 years of executive level experience in the life sciences industry
GARDEN CITY, N.Y., May 23, 2024 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of endogenous and exogenous nitric oxide (NO) to improve the lives of patients suffering from respiratory illnesses, neurological disorders and solid tumors (through its affiliate Beyond Cancer, Ltd.
Beyond Air (XAIR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Beyond Air, Inc. (XAIR) Q3 2024 Earnings Call Transcript
Beyond Air, Inc. (XAIR) came out with a quarterly loss of $0.50 per share versus the Zacks Consensus Estimate of a loss of $0.61. This compares to loss of $0.43 per share a year ago.
Beyond Air, Inc. (NASDAQ:XAIR ) Q2 2024 Earnings Conference Call November 13, 2023 4:30 PM ET Company Participants Edward Barger - Head of Investor Relations Steve Lisi - Chairman and Chief Executive Officer Duncan Fatkin - Chief Commercial Officer Douglas Larson - Chief Financial Officer Conference Call Participants Jeremy Jacoby - Truist Securities Marie Thibault - BTIG Matt Kaplan - Ladenburg Thalmann Operator Good afternoon and welcome everyone to the Beyond Air Financial Results Call for the Fiscal Quarter ended September 30, 2023. At this time, participants are in a listen-only mode.
GARDEN CITY, N.Y. and HAMILTON, Bermuda, Oct. 04, 2023 (GLOBE NEWSWIRE) -- Beyond Cancer, Ltd., an affiliate of Beyond Air, Inc. (NASDAQ: XAIR) that is developing ultra-high concentration nitric oxide (UNO) as an immunotherapeutic for solid tumors, today announced that Beyond Cancer, Ltd. will present two proffered posters at the upcoming American Association for Cancer Research-National Cancer Institute-European Organisation for Research and Treatment of Cancer (AACR-NCI-EORTC) International Conference on Molecular Targets and Cancer Therapeutics 2023, which is scheduled to be held October 11th – 15th in Boston, Massachusetts. Abstracts are scheduled to be released to AACR-NCI-EORTC registrants today 12:00 pm U.S. ET.
Beyond Air, Inc. (NASDAQ:XAIR ) Q1 2024 Earnings Conference Call August 10, 2023 4:30 PM ET Company Participants Edward Barger - Head of Investor Relations Steve Lisi - Chairman and Chief Executive Officer Duncan Fatkin - Chief Commercial Officer Douglas Larson - Chief Financial Officer Conference Call Participants Les Sulewski - Truist Securities Marie Thibault - BTIG Scott Henry - ROTH Capital Jason Bednar - Piper Sandler Matt Kaplan - Ladenburg Thalmann Yale Jen - Laidlaw & Company Operator Good afternoon and welcome everyone to the Beyond Air Financial Results Call for the Fiscal Quarter ended June 30, 2023. At this time, all participants are in a listen-only mode.
What type of business is Beyond Air?
Beyond Air, Inc. operates as a commercial medical device and biopharmaceutical company. The company engages in the development of LungFit platform, a nitric oxide generator and delivery system. It offers LungFit PH for the treatment of persistent pulmonary hypertension of the newborn. The company is also developing LungFit PRO for the treatment of viral lung infections, such as community-acquired viral pneumonia, including COVID-19, as well as bronchiolitis in hospitalized patients; and LungFit GO for the treatment of nontuberculous mycobacteria. The company was formerly known as AIT Therapeutics, Inc. and changed its name to Beyond Air, Inc. in June 2019. Beyond Air, Inc. is based in Garden City, New York.
What sector is Beyond Air in?
Beyond Air is in the Healthcare sector
What industry is Beyond Air in?
Beyond Air is in the Medical Devices industry
What country is Beyond Air from?
Beyond Air is headquartered in United States
When did Beyond Air go public?
Beyond Air initial public offering (IPO) was on 12 June 2018
What is Beyond Air website?
https://www.beyondair.net
Is Beyond Air in the S&P 500?
No, Beyond Air is not included in the S&P 500 index
Is Beyond Air in the NASDAQ 100?
No, Beyond Air is not included in the NASDAQ 100 index
Is Beyond Air in the Dow Jones?
No, Beyond Air is not included in the Dow Jones index
When does Beyond Air report earnings?
The next expected earnings date for Beyond Air is 09 August 2024